Nimodipine-d7 is the deuterium labeled Nimodipine. Nimodipine (BAY-e 9736) is an orally active, well-tolerated and light-sensitive dihydropyridine calcium antagonist. Nimodipine can be used for the research of cerebrovascular disorders[1].
体外研究 (In Vitro)
Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
分子量
425.48
Formula
C21H19D7N2O7
CAS 号
1246815-36-0
中文名称
尼莫地平 d7
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.
[2]. Langley, M.S., et al. Nimodipine. Drugs 37, 669–699 (1989).
[3]. Marbacher S, et al. Prevention of delayed cerebral vasospasm by continuous intrathecal infusion of glyceroltrinitrate and nimodipine in the rabbit model in vivo. Intensive Care Med. 2008;34(5):932-938.
[4]. Honn KV, et al. Inhibition of tumor cell-platelet interactions and tumor metastasis by the calcium channel blocker, nimodipine. Clin Exp Metastasis. 1984;2(1):61-72.
Nimodipine (BAY-e 9736) is an orally active, well-tolerated and light-sensitive dihydropyridine calcium antagonist. Nimodipine can be used for the research of cerebrovascular disorders[1].
IC50 & Target
dihydropyridine calcium[1]
体外研究 (In Vitro)
Nimodipine (1.5~150 μg/ml; 15 minutes; B16a and W256 cells) results in a dose-dependent inhibition of B16a and W256 tumor-cell-induced platelet aggregation. Nimodipine is also inhibitory in a homologous system[3].
上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究 (In Vivo)
Nimodipine (0.2 µg/µl, intrathecal administration) prevents subarachnoid hemorrhage-associated cerebral vasospasm by prophylactic continuous intrathecal administration[2]. Nimodipine(0.1~80 mg/kg; p.o.) results in a significant dose-dependent inhibition of spontaneous metastasis[3].
上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model:
New Zealand white rabbits[2]
Dosage:
0.2 µg/µl
Administration:
Intrathecal administration
Result:
Prevented subarachnoid hemorrhage-associated cerebral vasospasm by prophylactic continuous intrathecal administration.
Clinical Trial
分子量
418.44
Formula
C21H26N2O7
CAS 号
66085-59-4
中文名称
尼莫地平；硝苯比酯；硝苯甲氧乙基异丙啶
运输条件
Room temperature in continental US; may vary elsewhere.
[1]. Langley, M.S., et al. Nimodipine. Drugs 37, 669–699 (1989).
[2]. Marbacher S, et al. Prevention of delayed cerebral vasospasm by continuous intrathecal infusion of glyceroltrinitrate and nimodipine in the rabbit model in vivo. Intensive Care Med. 2008;34(5):932-938.
[3]. Honn KV, et al. Inhibition of tumor cell-platelet interactions and tumor metastasis by the calcium channel blocker, nimodipine. Clin Exp Metastasis. 1984;2(1):61-72.
